HRP20212034T1 - Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe - Google Patents
Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe Download PDFInfo
- Publication number
- HRP20212034T1 HRP20212034T1 HRP20212034TT HRP20212034T HRP20212034T1 HR P20212034 T1 HRP20212034 T1 HR P20212034T1 HR P20212034T T HRP20212034T T HR P20212034TT HR P20212034 T HRP20212034 T HR P20212034T HR P20212034 T1 HRP20212034 T1 HR P20212034T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- pharmaceutical preparation
- checkpoint inhibitor
- antigen
- cancer
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- 229940123751 PD-L1 antagonist Drugs 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229940125565 BMS-986016 Drugs 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- -1 CTLA4 antagonist Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000005746 immune checkpoint blockade Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229950011263 lirilumab Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Claims (14)
1. Protutijelo ili njegov fragment koji veže antigen, naznačeno time, da se veže na svaki od sljedećih antigenskih kompleksa:
i) ljudski LTBP1-proTGFβ1;
ii) ljudski LTBP3-proTGFβ1;
iii) ljudski GARP-proTGFβ1; i
iv) ljudski LRRC33-proTGFβ1;
pri čemu protutijelo ili njegov fragment koji veže antigen sadrži varijabilnu domenu teškog lanca prema SEQ ID NO: 13 i varijabilnu domenu lakog lanca prema SEQ ID NO: 15.
2. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1, naznačeno time, da se radi o ljudskom podtipu IgG4 ili IgG1.
3. Farmaceutski pripravak, naznačen time, da sadrži protutijelo ili njegov fragment koji veže antigen prema bilo kojem od prethodnih patentnih zahtjeva, i farmaceutski prihvatljiv nosač.
4. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time, da nadalje sadrži inhibitor kontrolne točke u istom farmaceutski prihvatljivom nosaču.
5. Farmaceutski pripravak prema patentnom zahtjevu 3 ili 4, naznačen time, da je za uporabu u liječenju raka.
6. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time, da je za uporabu u liječenju mijelofibroze.
7. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 5, gdje je u ovisnosti s patentnim zahtjevom 3, naznačen time, da se farmaceutski pripravak koristi u kombinaciji s inhibitorom kontrolne točke.
8. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 5, naznačen time, da pojedinac ima primarnu ili stečenu otpornost na liječenje raka, pri čemu je liječenje raka opcionalno terapija inhibicijom kontrolne točke, kemoterapija i/ili radijacijska terapija.
9. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 8, naznačen time, da liječenje obuhvaća primjenu pripravka, zajedno s dodatnom terapijom protiv raka odabranom iz skupine koju čine inhibitor kontrolne točke, kemoterapija i radijacijska terapija i/ili cjepivo protiv raka.
10. Farmaceutski pripravak, ili farmaceutski pripravak za uporabu, prema bilo kojem od patentnih zahtjeva 4, 7 ili 9, naznačen time, da se inhibitor kontrolne točke bira iz skupine koju čine antagonist PD-1, antagonist PD-L1, fuzijski protein PD-L1 ili PD-L2, antagonist CTLA4, agonist GITR, protutijelo anti-ICOS, protutijelo anti-ICOSL, protutijelo anti-B7H3, protutijelo anti-B7H4, protutijelo anti-TIM3, protutijelo anti-LAG3, protutijelo anti-OX40, protutijelo anti-CD27, protutijelo anti-CD70, protutijelo anti-CD47, protutijelo anti-41BB, protutijelo anti-PD-1, onkolitički virus, inhibitor PARP, nivolumab, pembrolizumab, BMS-936559, atezolizumab, avelumab, durvalumab, ipilimumab, tremelimumab, IMP-321, BMS-986016 i lirilumab.
11. Farmaceutski pripravak, ili farmaceutski pripravak za uporabu, prema patentnom zahtjevu 10, naznačen time, da inhibitor kontrolne točke je antagonist PD-1 ili antagonist PD-L1.
12. Farmaceutski pripravak, ili farmaceutski pripravak za uporabu, prema patentnom zahtjevu 11, naznačen time, da inhibitor kontrolne točke jest protutijelo anti-PD-1.
13. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 5 ili 7 do 12, naznačen time, da rak uključuje čvrsti tumor.
14. Postupak za proizvodnju farmaceutskog pripravka, naznačen time, da obuhvaća:
(i) pribavljanje protutijela ili njegovog fragmenta u skladu s bilo kojim od patentnih zahtjeva 1 do 2;
(ii) formuliranje protutijela ili njegovog fragmenta koji veže antigen u farmaceutski pripravak s farmaceutski prihvatljivim nosačem.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696752P | 2018-07-11 | 2018-07-11 | |
| US201862696774P | 2018-07-11 | 2018-07-11 | |
| US201862718196P | 2018-08-13 | 2018-08-13 | |
| US201862722081P | 2018-08-23 | 2018-08-23 | |
| US201862737534P | 2018-09-27 | 2018-09-27 | |
| US201862758180P | 2018-11-09 | 2018-11-09 | |
| US201862757917P | 2018-11-09 | 2018-11-09 | |
| US201962810263P | 2019-02-25 | 2019-02-25 | |
| US201962827552P | 2019-04-01 | 2019-04-01 | |
| EP19185896.8A EP3677278B1 (en) | 2018-07-11 | 2019-07-11 | Isoform selective tgfbeta1 inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20212034T1 true HRP20212034T1 (hr) | 2022-04-01 |
Family
ID=67437706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20212034TT HRP20212034T1 (hr) | 2018-07-11 | 2019-07-11 | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11130803B2 (hr) |
| EP (2) | EP4019046A1 (hr) |
| CY (1) | CY1125076T1 (hr) |
| DK (1) | DK3677278T3 (hr) |
| ES (1) | ES2905160T3 (hr) |
| HR (1) | HRP20212034T1 (hr) |
| HU (1) | HUE056501T2 (hr) |
| LT (1) | LT3677278T (hr) |
| MA (1) | MA52165A (hr) |
| PL (1) | PL3677278T3 (hr) |
| PT (1) | PT3677278T (hr) |
| RS (1) | RS62914B1 (hr) |
| SI (1) | SI3677278T1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011455A (es) * | 2020-03-19 | 2022-10-03 | Genentech Inc | Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso. |
| CN114645042A (zh) * | 2020-12-18 | 2022-06-21 | 中国食品药品检定研究院 | 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法 |
| EP4348260A2 (en) * | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| AU2022379208A1 (en) * | 2021-11-01 | 2024-06-13 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
| CN114236137A (zh) * | 2021-12-17 | 2022-03-25 | 中山大学·深圳 | 一种转化生长因子β的体外检测试剂盒及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| EP0889964A1 (en) | 1996-03-28 | 1999-01-13 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CA2411374C (en) | 2000-06-29 | 2012-10-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| US7803553B2 (en) | 2003-09-04 | 2010-09-28 | Riken | Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β |
| HUE042689T2 (hu) | 2005-02-08 | 2019-07-29 | Genzyme Corp | TGFbéta elleni antitestek |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| PE20100054A1 (es) | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
| AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| PT2780368T (pt) | 2011-11-14 | 2018-03-22 | Regeneron Pharma | Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a |
| CA3023553A1 (en) | 2012-11-06 | 2014-05-15 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| LT2981822T (lt) | 2013-05-06 | 2020-12-28 | Scholar Rock, Inc. | Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai |
| EP3139957A4 (en) | 2014-05-06 | 2018-04-25 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016201282A2 (en) | 2015-06-12 | 2016-12-15 | Ludwig Institute For Cancer Research Ltd | TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| JP2018527903A (ja) | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | Ｇｄｆ１１結合タンパク質およびその使用 |
| CN113896790A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
| US11643459B2 (en) | 2016-03-11 | 2023-05-09 | Scholar Rock, Inc. | TGFβ1-binding immunoglobulins and use thereof |
| AU2017294772B2 (en) | 2016-07-14 | 2024-05-02 | Scholar Rock, Inc. | TGFB antibodies, methods, and uses |
| MX2019008197A (es) | 2017-01-06 | 2019-09-11 | Scholar Rock Inc | Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. |
| WO2019023661A1 (en) | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF |
| EP3820508A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | High-affinity, isoform-selective tgf?1 inhibitors and use thereof |
| TW202019957A (zh) | 2018-07-11 | 2020-06-01 | 美商供石公司 | TGFβ1抑制劑及其用途 |
-
2019
- 2019-07-11 DK DK19185896.8T patent/DK3677278T3/da active
- 2019-07-11 EP EP21206768.0A patent/EP4019046A1/en active Pending
- 2019-07-11 ES ES19185896T patent/ES2905160T3/es active Active
- 2019-07-11 US US16/509,068 patent/US11130803B2/en active Active
- 2019-07-11 PL PL19185896T patent/PL3677278T3/pl unknown
- 2019-07-11 HU HUE19185896A patent/HUE056501T2/hu unknown
- 2019-07-11 LT LTEP19185896.8T patent/LT3677278T/lt unknown
- 2019-07-11 MA MA052165A patent/MA52165A/fr unknown
- 2019-07-11 SI SI201930143T patent/SI3677278T1/sl unknown
- 2019-07-11 HR HRP20212034TT patent/HRP20212034T1/hr unknown
- 2019-07-11 EP EP19185896.8A patent/EP3677278B1/en active Active
- 2019-07-11 PT PT191858968T patent/PT3677278T/pt unknown
- 2019-07-11 RS RS20220099A patent/RS62914B1/sr unknown
-
2021
- 2021-08-19 US US17/406,400 patent/US20220064275A1/en active Pending
-
2022
- 2022-01-28 CY CY20221100075T patent/CY1125076T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3677278B1 (en) | 2021-11-10 |
| ES2905160T3 (es) | 2022-04-07 |
| SI3677278T1 (sl) | 2022-01-31 |
| PT3677278T (pt) | 2022-02-03 |
| RS62914B1 (sr) | 2022-03-31 |
| US11130803B2 (en) | 2021-09-28 |
| CY1125076T1 (el) | 2023-06-09 |
| EP3677278A1 (en) | 2020-07-08 |
| US20220064275A1 (en) | 2022-03-03 |
| HUE056501T2 (hu) | 2022-02-28 |
| LT3677278T (lt) | 2022-01-10 |
| DK3677278T3 (da) | 2022-01-10 |
| PL3677278T3 (pl) | 2022-02-28 |
| MA52165A (fr) | 2021-06-02 |
| EP4019046A1 (en) | 2022-06-29 |
| US20200079840A1 (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20212034T1 (hr) | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe | |
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| HRP20201404T1 (hr) | Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita | |
| JP2020099324A5 (hr) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| Aranda et al. | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy | |
| HRP20190749T1 (hr) | Ljudska antitijela na pd-l1 | |
| JP2018532383A5 (hr) | ||
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| JP2018501197A5 (hr) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2020516240A5 (hr) | ||
| RU2017105118A (ru) | Нейтрализация ингибирующих путей в лимфоцитах | |
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018508483A5 (hr) | ||
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2018508512A5 (hr) | ||
| HRP20231664T1 (hr) | Nova anti-pd-l1 antitijela | |
| JP2018520657A5 (hr) | ||
| JP2017501157A5 (hr) | ||
| JP2017537090A5 (hr) | ||
| RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |